Tcr2 Therapeutics
(NASDAQ) TCRR
Tcr2 Therapeutics Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$0.00
Net Income (TTM)
$163.10M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
TCRR News
TCRR: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Tcr2 Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
66
CEO
Garry E. Menzel, PhD, MBA
Website
www.tcr2.comHeadquarters
Cambridge, MA 02142, US
TCRR Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-72%
Return on Capital
-1%
Return on Assets
-73%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$0.00
Operating Income
$153.50M
EBITDA
$89.62M
Operating Cash Flow
$101.46M
Capital Expenditure
$15.45M
Free Cash Flow
$116.91M
Cash & ST Invst.
$149.18M
Total Debt
$53.76M
Tcr2 Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$0.00
N/A
Gross Margin
0.00%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
58
N/A
Net Income
$40.40M
-38.7%
EBITDA
$32.81M
-16.1%
Quarterly Fundamentals
Net Cash
$104.33M
-41.6%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$2.71M
-92.6%
Short Term Debt
$3.27M
-80.7%
Return on Assets
-72.91%
N/A
Return on Invested Capital
-1.06%
N/A
Free Cash Flow
$40.17M
-21.3%
Operating Cash Flow
$40.01M
-28.5%